行情

ZYNE

ZYNE

Zynerba Pharms
NASDAQ

实时行情|Nasdaq Last Sale

5.67
+0.04
+0.62%
交易中 12:31 12/09 EST
开盘
5.70
昨收
5.63
最高
5.73
最低
5.58
成交量
10.17万
成交额
--
52周最高
16.47
52周最低
2.750
市值
1.31亿
市盈率(TTM)
-3.7787
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ZYNE 新闻

  • iRobot Corporation (IRBT), Zendesk, Inc. (ZEN) & Zynerba Pharmaceuticals, Inc. (ZYNE)- Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Actions
  • ACCESSWIRE.2小时前
  • ZYNE NOTICE: Pawar Law Group Reminds Investors of Deadline in Securities Class Action Lawsuit Against Zynerba Pharmaceuticals, Inc. ZYNE
  • GlobeNewswire.2天前
  • Is Zynerba Pharmaceuticals (ZYNE) Stock Outpacing Its Medical Peers This Year?
  • Zacks.3天前
  • iRobot Corporation (IRBT), Zendesk, Inc. (ZEN) & Zynerba Pharmaceuticals, Inc. (ZYNE) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Actions
  • GlobeNewswire.3天前

更多

所属板块

生物技术和医学研究
-0.83%
制药与医学研究
-0.47%

热门股票

名称
价格
涨跌幅

ZYNE 简况

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.
展开

Webull提供Zynerba Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。